| Melissa S Williams, MD | |
|
442 W High St, Bryan, OH 43506-1681 | |
| (419) 636-4517 | |
| Not Available |
| Full Name | Melissa S Williams |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 12 Years |
| Location | 442 W High St, Bryan, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891052163 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35.131008 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Parkview Regional Medical Center | Fort wayne, IN | Hospital |
| Mercy Health - Defiance Hospital | Defiance, OH | Hospital |
| Promedica Defiance Regional Hospital | Defiance, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Community Health Associates, Inc. | 0941114250 | 49 |
News Archive
Porous ceramic water filters are often coated with colloidal silver, which prevents the growth of microbes trapped in the micro- and nano-scale pores of the filter. Other metals such as copper and zinc have also been shown to exhibit anti-microbial activity.
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.
Protego Medical Pty Ltd, an early stage medical technology company developing a medical device for sternal protection during cardiac surgery, was launched today with AU$2M start-up financing from Australia's Medical Research Commercialisation Fund (MRCF). At the same time, the Company announced the appointment of Pablo Solis as CEO.
› Verified 6 days ago
| Entity Name | Midwest Community Health Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619915170 PECOS PAC ID: 0941114250 Enrollment ID: O20031231000726 |
News Archive
Porous ceramic water filters are often coated with colloidal silver, which prevents the growth of microbes trapped in the micro- and nano-scale pores of the filter. Other metals such as copper and zinc have also been shown to exhibit anti-microbial activity.
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.
Protego Medical Pty Ltd, an early stage medical technology company developing a medical device for sternal protection during cardiac surgery, was launched today with AU$2M start-up financing from Australia's Medical Research Commercialisation Fund (MRCF). At the same time, the Company announced the appointment of Pablo Solis as CEO.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa S Williams, MD 11109 Parkview Plaza Dr # 117, Fort Wayne, IN 46845-1701 Ph: () - | Melissa S Williams, MD 442 W High St, Bryan, OH 43506-1681 Ph: (419) 636-4517 |
News Archive
Porous ceramic water filters are often coated with colloidal silver, which prevents the growth of microbes trapped in the micro- and nano-scale pores of the filter. Other metals such as copper and zinc have also been shown to exhibit anti-microbial activity.
The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.
Protego Medical Pty Ltd, an early stage medical technology company developing a medical device for sternal protection during cardiac surgery, was launched today with AU$2M start-up financing from Australia's Medical Research Commercialisation Fund (MRCF). At the same time, the Company announced the appointment of Pablo Solis as CEO.
› Verified 6 days ago